2018 Arrhythmia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Arrhythmia Market
Arrhythmia or cardiac dysrhythmia refers to abnormal rate of heart beats and effects around 6 million people in the US alone. More than 20% of these patients are hospitalized and 8-9% witness death. The pace of heart beat is irregular, or either more than the normal range (tachycardia) or slower than normal (bradycardia). Primary factors contributing to the Arrhythmia condition include diabetes, smoking, stress while symptoms include palpitations, short of breath etc.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Arrhythmia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Arrhythmia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Arrhythmia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Arrhythmia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Arrhythmia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Arrhythmia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ARRHYTHMIA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Arrhythmia Pipeline Snapshot
2.3 Arrhythmia Pipeline by Phase
2.4 Arrhythmia Pipeline by Company
2.5 Arrhythmia Pipeline by Mechanism of Action
3 ARRHYTHMIA- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd
Armgo Pharma, Inc.
Beijing CoSci Med-Tech Co.,Ltd
Gilead Sciences, Inc.
HUYA Bioscience International, LLC
InCarda Therapeutics, Inc.
LATITUDE Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Numerate, Inc.
OMEICOS Therapeutics GmbH
Ono Pharmaceutical Co., Ltd.
Sanofi SA
Servier Laboratories Limited
Sign Path Pharma Inc
4 ARRHYTHMIA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ARRHYTHMIA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ARRHYTHMIA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Arrhythmia Pipeline Snapshot
2.3 Arrhythmia Pipeline by Phase
2.4 Arrhythmia Pipeline by Company
2.5 Arrhythmia Pipeline by Mechanism of Action
3 ARRHYTHMIA- COMPANY WISE PIPELINE ANALYSIS
AETAS Pharma Co.,Ltd
Armgo Pharma, Inc.
Beijing CoSci Med-Tech Co.,Ltd
Gilead Sciences, Inc.
HUYA Bioscience International, LLC
InCarda Therapeutics, Inc.
LATITUDE Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Numerate, Inc.
OMEICOS Therapeutics GmbH
Ono Pharmaceutical Co., Ltd.
Sanofi SA
Servier Laboratories Limited
Sign Path Pharma Inc
4 ARRHYTHMIA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ARRHYTHMIA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Arrhythmia Pipeline by Phase, H2- 2018
Figure 2: Arrhythmia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Arrhythmia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Arrhythmia Pipeline by Phase, H2- 2018
Figure 2: Arrhythmia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Arrhythmia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Arrhythmia Pipeline by Phase, H2- 2018
Arrhythmia Pipeline by Companies, H2- 2018
Arrhythmia Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd Arrhythmia Pipeline Drugs, H2- 2018
Table 2: Armgo Pharma, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Arrhythmia Pipeline Drugs, H2- 2018
Table 4: Gilead Sciences, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 5: HUYA Bioscience International, LLC Arrhythmia Pipeline Drugs, H2- 2018
Table 6: InCarda Therapeutics, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 7: LATITUDE Pharmaceuticals Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 8: Milestone Pharmaceuticals Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 9: Numerate, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 10: OMEICOS Therapeutics GmbH Arrhythmia Pipeline Drugs, H2- 2018
Table 11: Ono Pharmaceutical Co., Ltd. Arrhythmia Pipeline Drugs, H2- 2018
Table 12: Sanofi SA Arrhythmia Pipeline Drugs, H2- 2018
Table 13: Servier Laboratories Limited Arrhythmia Pipeline Drugs, H2- 2018
Table 14: Sign Path Pharma Inc Arrhythmia Pipeline Drugs, H2- 2018
Arrhythmia Pipeline by Phase, H2- 2018
Arrhythmia Pipeline by Companies, H2- 2018
Arrhythmia Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd Arrhythmia Pipeline Drugs, H2- 2018
Table 2: Armgo Pharma, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Arrhythmia Pipeline Drugs, H2- 2018
Table 4: Gilead Sciences, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 5: HUYA Bioscience International, LLC Arrhythmia Pipeline Drugs, H2- 2018
Table 6: InCarda Therapeutics, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 7: LATITUDE Pharmaceuticals Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 8: Milestone Pharmaceuticals Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 9: Numerate, Inc. Arrhythmia Pipeline Drugs, H2- 2018
Table 10: OMEICOS Therapeutics GmbH Arrhythmia Pipeline Drugs, H2- 2018
Table 11: Ono Pharmaceutical Co., Ltd. Arrhythmia Pipeline Drugs, H2- 2018
Table 12: Sanofi SA Arrhythmia Pipeline Drugs, H2- 2018
Table 13: Servier Laboratories Limited Arrhythmia Pipeline Drugs, H2- 2018
Table 14: Sign Path Pharma Inc Arrhythmia Pipeline Drugs, H2- 2018
